EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s Disease

BACKGROUND: Gocovri(®) (amantadine) extended release capsules are approved for the treatment of dyskinesia in patients with Parkinson’s disease (PD) receiving levodopa-based therapy. OBJECTIVE: To evaluate the long-term safety, tolerability, and efficacy of Gocovri in patients with PD experiencing l...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Parkinsons Dis
Main Authors: Tanner, Caroline M., Pahwa, Rajesh, Hauser, Robert A., Oertel, Wolfgang H., Isaacson, Stuart H., Jankovic, Joseph, Johnson, Reed, Chernick, Dustin, Hubble, Jean
Formato: Artigo
Idioma:Inglês
Publicado: IOS Press 2020
Assuntos:
Research Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7242830/
https://ncbi.nlm.nih.gov/pubmed/31929122
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/JPD-191841
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares